According to the World Health Organization (WHO), the population of people suffering from diabetes globally is approaching 9%. Credit: ivector/shutterstock

US-based diabetes technology company, Tandem Diabetes Care has received US Food and Drug Administration (FDA) clearance for its Tandem Mobi insulin delivery system.

The device, which is expected to become available on the market towards the end of 2023, has been dubbed by the company as the ‘world’s smallest insulin pump’. Full commercial availability is planned for early 2024.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Following the news of the clearance, Tandem Diabetes CEO, John Sheridan said: “Testing the limits of pump miniaturization, Tandem Mobi joins the t:slim X2 pump in our family of insulin delivery solutions bringing new options in wearability, the flexibility to disconnect, and full phone control.”

Tandem Mobi will come with control-IQ technology, a hybrid-closed loop algorithm to be used by people with type 1 diabetes from the age of six. The technology uses compatible continuous glucose monitoring (CGM) sensor values to forecast glucose levels 30 minutes ahead and adjust insulin delivery every 5 minutes to help prevent highs and lows. Users will also be able to manually administer insulin for meals.

The company’s share price jumped almost 5 points from 24.76 cents a share on Monday 10 July to 29.10 cents a share on Tuesday the 11 July when the FDA clearance was announced. To date, the share price was below the average and low market sentiment.

According to the World Health Organization (WHO), the population of people suffering from diabetes globally is approaching 9%, indicating that market demand for diabetes devices will grow.

In a GlobalData report, the North America Insulin Delivery market was valued at $5,010.2 million in 2015 and the market is expected to reach $8,494.4 million in 2025. Unit sales are expected to grow from 147,047,114 to 276,125,032 in the same time.